# 5-amino-1MQ blocks the enzyme that throws away vitamin B3, and three currencies move at once

slug: 5-amino-1mq · https://miscsubjects.com/a/5-amino-1mq · category: compound · tags: 5-amino-1mq, NNMT, NAD+, SAM, polyamines, preclinical · updated 2026-08-05T09:39:22.724Z

5-amino-1MQ blocks an enzyme that sits at a junction between three different things your cells need: the molecule that carries energy transactions, the molecule that donates methyl groups, and a set of small compounds called polyamines. Blocking it in obese mice made them lose fat. It has never been given to a person in a published trial.

That is the whole compound in three sentences, and the interesting part is not the fat loss. It is the junction.

## What NNMT actually does, and why blocking it does several things at once

The enzyme is nicotinamide N-methyltransferase, NNMT. Its job is simple to state: it takes nicotinamide — a form of vitamin B3 — and attaches a methyl group to it. A methyl group is a single carbon with three hydrogens, the smallest chemical tag cells use to mark things. The result is 1-methylnicotinamide, which the cell then excretes.

So NNMT is a disposal enzyme. It takes vitamin B3 and throws it away in a form that cannot be recycled.

Now look at what it consumes doing that, because this is where the compound gets interesting. The Nature paper that identified the target explains it precisely: "NNMT methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. Nicotinamide is a precursor of NAD(+), an important cofactor linking cellular redox states with energy metabolism. SAM provides propylamine for polyamine biosynthesis and donates a methyl group for histone methylation."

Unpack that and you get three separate consequences of one enzyme running.

**It destroys NAD⁺ precursor.** Nicotinamide is the raw material your cell uses to make NAD⁺, the molecule that carries electrons in every energy-producing reaction you run. Methylating nicotinamide takes it permanently out of that supply chain. Every NAD⁺ booster sold — nicotinamide riboside, NMN, plain niacinamide — is an attempt to push more material into the front of that chain. Inhibiting NNMT is an attempt to stop material leaking out of the back of it.

**It burns through SAM.** S-adenosylmethionine is the cell's universal methyl donor. It is what marks DNA and histones — the proteins your DNA is wound around — and those marks determine which genes are switched on. Every methylation reaction in your cell competes for the same SAM pool. An enzyme consuming SAM at high rates to dispose of vitamin B3 is spending a budget that gene regulation also draws on.

**It competes with polyamine synthesis.** SAM also supplies propylamine for making polyamines — spermidine and spermine — which the paper notes have "a major role in energy metabolism."

So one enzyme, three currencies. Inhibit it and all three should move at once. That is unusual, and it is why NNMT attracted interest as a target rather than as a curiosity.

## The finding that started it

The 2014 Nature paper did not set out to study NNMT. It was looking at Glut4, the glucose transporter that fat cells lose in obesity and diabetes. Using gene arrays across mice engineered to lack or overexpress Glut4 in fat, the authors found "that nicotinamide N-methyltransferase (Nnmt) is the most strongly reciprocally regulated gene."

Most strongly, out of the whole array. That is the kind of result that redirects a laboratory. Then: "We report that NNMT expression is increased in WAT and liver of obese and diabetic mice."

And the experiment that made it a drug target: "Nnmt knockdown in WAT and liver protects against diet-induced obesity by augmenting cellular energy expenditure."

Note the mechanism named in that sentence. Not reduced appetite — increased energy expenditure. The mice were not eating less; their cells were spending more.

The paper then traced the pathway all the way through, and this is why it is a genuinely strong piece of work rather than an association. "NNMT inhibition increases adipose SAM and NAD(+) levels and upregulates ODC and SSAT activity as well as expression, owing to the effects of NNMT on histone H3 lysine 4 methylation in adipose tissue." So the SAM that was being spent on disposal became available, showed up as changed histone marks, and those marks turned up the enzymes that control polyamine flux.

Then they confirmed it in urine: "Direct evidence for increased polyamine flux resulting from NNMT inhibition includes elevated urinary excretion and adipocyte secretion of diacetylspermine, a product of polyamine metabolism."

That last step is what separates a mechanism from a story. They predicted a specific waste product should appear if their model was right, and it appeared.

Finally, oxygen consumption — the direct measure of a cell burning fuel — rose, "in an ODC-, SSAT- and PAO-dependent manner." Knock out the polyamine enzymes and the effect disappears, which demonstrates the pathway is the cause rather than a bystander.

The paper's own summary of what NNMT is: "a novel regulator of histone methylation, polyamine flux and NAD(+)-dependent SIRT1 signalling, and is a unique and attractive target for treating obesity and type 2 diabetes."

## Where 5-amino-1MQ comes in

The 2014 work used genetic knockdown, which is not a drug. Turning it into one required a molecule that could get inside a cell, hit NNMT and not hit everything adjacent to it. That is the 2018 paper in *Biochemical Pharmacology*, and its title is the finding: "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice."

Three words in that title carry the work. **Membrane-permeable**: NNMT is inside the cell, so an inhibitor that cannot cross the membrane is useless regardless of how well it binds. **Selective**: the compound has to leave alone the structurally similar methyltransferases and the NAD⁺ salvage enzymes, or the effect is not attributable to NNMT. **Reverse**: the mice were already obese when treatment began.

The authors describe testing exactly those properties: "we investigated the permeability, selectivity, mechanistic, and physiological properties of a series of small molecule NNMT inhibitors. Membrane permeability of NNMT inhibitors was characterized using parallel artificial membrane permeability and Caco-2 cell assays. Selectivity was tested against structurally-related methyltransferases and nicotinamide adenine dinucleotide (NAD+) salvage pathway enzymes."

That is a careful drug-discovery paper rather than an enthusiastic one. Permeability measured two independent ways, selectivity measured against the enzymes most likely to confound the result.

The doses in that work were given by injection, several times daily, over days. That is the only dosing evidence that exists for this compound, and it is in mice.

## Why the three currencies matter more than the fat loss

It is worth staying with the mechanism, because it is the reason this compound is discussed at all and it is almost always skipped in favour of the weight number.

**NAD⁺.** Every reaction that extracts energy from food hands electrons to NAD⁺. It also feeds the sirtuins, a family of enzymes that strip acetyl marks off proteins and cannot work without it, and PARP enzymes that repair damaged DNA and consume it heavily. NAD⁺ falls with age, and the entire supplement industry built on nicotinamide riboside and NMN exists to push more precursor into the front of that pathway. NNMT sits at the other end, quietly disposing of the same precursor. Blocking a leak and opening a tap are different interventions with the same intended effect, and nobody has compared them in a person.

**SAM.** Every methylation reaction in the cell — on DNA, on histones, on neurotransmitters, on phospholipids — draws from one shared pool of S-adenosylmethionine. That means these reactions compete. An enzyme spending SAM at high rates to throw away vitamin B3 is a competitor for the budget gene regulation uses, and the 2014 paper measured exactly that consequence: inhibiting NNMT changed histone H3 lysine 4 methylation in fat tissue. Gene expression shifted because a methyl budget was freed.

That is the part to sit with. This is not a drug that changes one number. It changes which genes are marked, in a tissue, by changing how a shared resource is spent. That is a powerful mechanism and it is precisely why the unstudied long-term consequences are not a formality.

**Polyamines.** Spermidine and spermine are involved in cell growth, autophagy and energy metabolism, and their flux is controlled by the rate-limiting enzymes the paper names — ODC, SSAT and polyamine oxidase. The oxygen-consumption increase in treated adipocytes disappeared when those enzymes were blocked, which is the strongest single piece of evidence in the whole literature that the polyamine arm is doing the work rather than accompanying it.

## What the mouse numbers are and are not

The figures that circulate for this compound — body weight down, white fat mass down, adipocytes smaller, cholesterol lower, food intake unchanged — come from the 2018 small-molecule work in diet-induced obese mice, given by injection several times daily over days.

Two things about them. The unchanged food intake is the load-bearing detail, because it means the effect was on expenditure rather than on appetite, which is what the mechanism predicts and what makes the result internally consistent. And the species gap for metabolic endpoints is the widest in pharmacology: a mouse runs its metabolism several times faster per unit of mass than you do, carries proportionally far more brown fat, and is mildly cold-stressed at ordinary laboratory temperature, all of which flatter interventions that raise energy expenditure. That is the specific reason a long list of compounds that transformed mice did nothing in people.

So the numbers are real measurements of a real effect in an animal whose energy metabolism does not work like yours. Enough to justify pursuing the target. Not enough to predict a person.

## What a page selling this will not tell you

**There are no human trials.** Not one. Not a phase I, not a safety study, not a pharmacokinetic run. Every number attached to 5-amino-1MQ came out of a mouse or a dish.

**The core evidence is a knockdown, not the drug.** The Nature paper's mechanistic depth — the histone marks, the polyamine flux, the diacetylspermine in urine, the enzyme-dependency controls — is all from genetic knockdown of NNMT. The small-molecule paper shows a molecule can reproduce the physiological outcome. It does not re-establish the whole mechanism.

**NNMT is not only in fat.** The 2014 paper reports NNMT elevated in white adipose tissue *and liver*. The enzyme is also expressed in other tissues and is studied heavily in cancer biology, where its role is not a simple one. Inhibiting a methyltransferase that influences histone methylation is not a local intervention, and the long-term consequences of shifting the SAM budget across tissues have not been studied in any species.

**It is not a NAD⁺ booster, and it is not a peptide.** It is a small molecule that stops NAD⁺ precursor being thrown away. That is a different mechanism from supplying more precursor, and the two have never been compared head to head in a person. It is also constantly sold as a peptide. It is not one — no amino acid chain, no injection requirement from its chemistry.

**The regulation runs on glucose.** A 2020 study found NNMT expression in adipocytes responds to glucose availability, with glucose deprivation increasing it. So the enzyme this compound blocks is itself under nutritional control, which means baseline diet is a variable in any effect and nobody has measured how large a one.

## The interactions worth reasoning about, and why they cannot be listed

No drug-interaction work has been published for this compound. The enzymes that metabolise it, its half-life, its plasma protein binding — none of that exists in the literature, so anyone giving you a specific interaction list has written it rather than read it. What can be reasoned about is the mechanism, and three things follow from it.

**Anything else acting on the NAD⁺ pool.** Nicotinamide riboside, NMN, plain nicotinamide and niacin all push precursor into the pathway NNMT drains. Combining them is not obviously harmful and it is entirely unstudied, and there is a specific reason to be curious rather than confident: plain nicotinamide at high doses is itself a substrate for NNMT, so the interaction is not simply additive. Nobody has measured which way it goes.

**Anything competing for the SAM pool.** SAM-e as a supplement, methylfolate, methylcobalamin, betaine and choline all sit in the methylation economy, and so do the drugs that draw on it heavily — levodopa consumes SAM through COMT-mediated methylation, and so do several others. The whole premise of inhibiting NNMT is to change how a shared methyl budget is spent, which makes anything else spending from that budget a genuine unknown rather than a theoretical one.

**Anything acting on polyamines or autophagy.** Spermidine supplementation is sold on the same shelf and acts on the arm of this mechanism the 2014 paper showed to be load-bearing. Pushing the same pathway from two directions with no human data on either is compounding an unknown.

The honest summary of the interaction section is that there is nothing to report and specific reasons to expect the interactions are not trivial. That is more useful than a confident list somebody invented.

## What it is genuinely useful for thinking about

The reason to know about NNMT is not that 5-amino-1MQ works. It is that the enzyme is the clearest published example of a single node where energy metabolism, gene regulation and polyamine flux intersect — and the 2014 paper walked the whole chain, from gene array to histone mark to urinary metabolite to oxygen consumption, with the controls to show the pathway was load-bearing.

What is unresolved is everything about the drug. Whether a person tolerates NNMT inhibition, at what dose, with what effect on the tissues where the enzyme does something other than dispose of vitamin B3, and whether the fat-loss effect survives translation out of an animal whose metabolic rate is several times yours. Those are not gaps in the reading. They are experiments that have not been run.

## The name, and one thing it tells you

The name is a chemical description, and reading it is worth thirty seconds because it explains what the molecule is doing.

1MQ is 1-methylquinolinium — a quinoline ring carrying a methyl group on its nitrogen, which gives the nitrogen a permanent positive charge. The "5-amino" is an amine group added at the fifth position on that ring.

Now compare that to the enzyme's actual product. NNMT takes nicotinamide and methylates its ring nitrogen, producing 1-methylnicotinamide — a ring with a methylated, positively charged nitrogen. 5-amino-1MQ is a close structural imitation of that product, which is why it binds where it does. It is a product-mimicking inhibitor: the enzyme's own output, rebuilt in a form it cannot let go of.

Two practical things follow. It is a small aromatic molecule, not a peptide, whatever the shelf it is sold on says. And its permanent positive charge is precisely why the 2018 paper had to measure membrane permeability two separate ways — permanently charged molecules cross membranes poorly as a rule, and NNMT is inside the cell, so permeability was the real obstacle rather than binding. That the compound crosses at all is the actual achievement of that paper.

Everything above is what the published record supports. None of it is medical advice, and 5-amino-1MQ is sold for research use only, not for human consumption.


## Sources

1. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity — https://pubmed.ncbi.nlm.nih.gov/24717514/
2. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity — https://pubmed.ncbi.nlm.nih.gov/24717514/
3. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity — https://pubmed.ncbi.nlm.nih.gov/24717514/
4. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity — https://pubmed.ncbi.nlm.nih.gov/24717514/
5. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity — https://pubmed.ncbi.nlm.nih.gov/24717514/
6. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice — https://pubmed.ncbi.nlm.nih.gov/29155147/
7. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice — https://pubmed.ncbi.nlm.nih.gov/29155147/
8. Glucose availability regulates nicotinamide N-methyltransferase expression in adipocytes — https://pubmed.ncbi.nlm.nih.gov/32112869/


---

# SLU-PP-332 is a chemical tool that switches on the endurance-training programme in muscle

slug: slu-pp-332 · https://miscsubjects.com/a/slu-pp-332 · category: compound · tags: slu-pp-332, ERR agonist, exercise mimetic, mitochondria, preclinical · updated 2026-08-05T09:39:20.822Z

SLU-PP-332 is a small molecule that turns on a genetic programme normally switched on by hard aerobic exercise. In mice it does roughly what a run does to muscle. It has never been given to a human being in a published study, and it was not built to be a drug.

That last part matters more than anything else about it, so it goes first. The paper that introduced it describes it as a chemical tool: the authors say it "has sufficient pharmacokinetic properties to be used as an in vivo chemical tool." A tool is something you use to find out whether an idea is worth pursuing. It is not a candidate you intend to put in people. Compounds designed as drugs get years of work on absorption, half-life, off-target effects and toxicology before anyone considers a first human dose. SLU-PP-332 got enough of that to survive an experiment in a mouse.

## What ERR is, and why anyone went looking for a molecule that hits it

Inside almost every cell in your body there are proteins whose whole job is to switch genes on. They sit in the cell, wait for a signal, and when the signal arrives they bind to DNA and start production of whichever proteins that gene encodes. They are called nuclear receptors, because they work in the nucleus where the DNA is.

Three of them are called estrogen-related receptors — ERRα, ERRβ and ERRγ. The name is a historical accident. They look structurally similar to the receptor that oestrogen binds to, which is how they were first identified, but oestrogen does not bind to them and they have nothing to do with sex hormones. They are called "orphan" receptors because nobody has found the natural signal that switches them on. We know what they do without knowing what tells them to do it.

What they do is run mitochondria. Mitochondria are the structures inside cells that convert fuel into usable energy, and a muscle cell that has done a lot of endurance work has more of them, and better ones. ERRα in particular controls a large set of genes governing how many mitochondria a muscle has, how well they work, and whether the muscle prefers to burn fat or sugar. When you train for endurance, ERR activity is part of what carries out the resulting change.

So the reasoning was direct: if ERR carries out the adaptation, a molecule that activates ERR should produce the adaptation without the training. That reasoning was easier to state than to act on. The paper introducing SLU-PP-332 says why: "although ERRβ/γ agonists have been designed, there have been significant difficulties in designing compounds with ERRα agonist activity." ERRα was the one that mattered most and the one nobody could hit. SLU-PP-332's actual achievement is that it hits all three, "but has the highest potency for ERRα."

## What happened in the mice

Two studies carry almost all of the evidence.

The first, in *ACS Chemical Biology* in 2023, established what the molecule does. In cells it "increases mitochondrial function and cellular respiration in a skeletal muscle cell line." In animals it changed the muscle itself: "When administered to mice, SLU-PP-332 increased the type IIa oxidative skeletal muscle fibers and enhanced exercise capacity." Type IIa fibres are the intermediate kind — faster than the slow endurance fibres, far more fatigue-resistant than the fast explosive ones, and rich in mitochondria. Growing the type IIa share is one of the specific things endurance training does. The compound produced that change in animals that had not trained.

The second, in the *Journal of Pharmacology and Experimental Therapeutics* in January 2024, asked whether that translated into metabolic benefit in obese animals. Diet-induced obese mice and ob/ob mice — a strain genetically unable to produce leptin, so they overeat and become obese — were given the compound. The result, in the paper's words: "SLU-PP-332 administration mimics exercise-induced benefits on whole-body metabolism in mice including increased energy expenditure and fatty acid oxidation. These effects were accompanied by decreased fat mass accumulation. Additionally, the ERR agonist effectively reduced obesity and improved insulin sensitivity in models of metabolic syndrome."

Read what that says and what it does not. It says energy expenditure went up, fat oxidation went up, fat accumulation went down, and insulin sensitivity improved. It says this in mice. The paper's own significance statement keeps the qualifier attached: the compound "holds promise as a therapeutic to treat metabolic diseases by decreasing fat mass in mouse models of obesity."

The figures that circulate — 70 percent longer running time, 45 percent further, roughly ten times less fat gained, 12 percent body weight lost — come from these studies and from the university's press coverage of them. They are real numbers from real experiments. They are also mouse numbers, and mouse metabolic numbers are among the least reliable predictors of human outcomes in all of pharmacology, because a mouse burns energy at a completely different rate relative to its size and its brown fat behaves differently from an adult human's.

## The heart, and why it cuts both ways

There is a third study worth knowing about, and it is the most interesting one, because it points at both the promise and the risk.

Published in *Circulation* in January 2024, it tested pan-ERR agonists in heart failure. The title states the finding: "Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function." A failing heart has a characteristic metabolic defect — it loses the ability to burn fat efficiently and falls back on less efficient fuel, which makes the failure worse. Restoring fat oxidation in cardiac muscle is a real therapeutic idea, and in these animal models the ERR agonists did it.

That is genuinely good news for the mechanism. It is also the clearest statement available that this compound acts on the heart. Cardiac muscle is dense with mitochondria and dense with ERR. A molecule that reprogrammes mitochondrial metabolism does not confine itself to your quadriceps. In a diseased heart with a known metabolic defect that reprogramming helped. Nobody has published what it does to a structurally normal human heart over months, because nobody has run that study.

A fourth study, in the *American Journal of Pathology* in December 2023, found ERR agonism "reverses mitochondrial dysfunction and inflammation in the aging kidney." Same pattern: another organ, another mitochondria-dense tissue, another real effect. The mechanism is systemic. That is the point of it and also the thing to be careful about.

## What "exercise mimetic" does and does not mean

The phrase does a lot of work and most of it is misleading, so it is worth taking apart.

Exercise is not one thing. A hard hour of aerobic work does at least a dozen distinguishable things to you. It builds mitochondria in the muscles that did the work. It shifts fibre composition toward fatigue resistance. It grows new capillaries into those muscles so more blood reaches them. It improves how sensitively your tissues respond to insulin. It strengthens the heart as a pump, raising the volume it moves per beat. It loads bone and tendon, which is the signal that keeps both dense and strong. It raises brain-derived neurotrophic factor, which is part of why training affects mood and memory. It improves how well the lining of your blood vessels dilates. It clears fat out of the bloodstream after meals. It changes appetite regulation. It improves sleep. And it does all of this in proportion to the work done, in the tissues that did the work, over weeks.

SLU-PP-332 addresses the first two of those and touches a third. It builds mitochondria and shifts fibre type, and it raises fat oxidation, which is downstream of the same programme. It does not load your bones. It does not build capillaries into a muscle that never contracted. It does not strengthen the heart as a pump — it changes cardiac metabolism, which is a different thing. It does not improve tendon strength, which is the tissue most likely to be the limiting factor when someone with new metabolic capacity starts training harder.

So "exercise mimetic" is accurate in the narrow, technical sense the researchers use it: the compound activates a genetic programme that acute aerobic exercise also activates. It is inaccurate in the sense a reader will take it, which is "does what exercise does." A molecule that grows mitochondria in a sedentary animal is a genuinely interesting result. It is not a substitute for the training and it was never claimed to be, by anyone who did the work.

## Doses, and why the numbers you see are invented

The published animal work used doses in the range of tens of milligrams per kilogram, given by injection, over days to weeks. Those are the only real numbers that exist for this compound.

Converting an animal dose to a human one is not multiplication. The standard method scales by body surface area rather than weight, because small animals run their metabolism faster relative to their size, and even that method is a rough approximation that assumes you know how fast each species clears the compound. For SLU-PP-332 nobody knows how fast a human clears it, because no human has been given a measured dose and had their blood drawn. Its half-life in people is unknown. Its oral bioavailability in people is unknown. Whether it reaches muscle tissue in a person at any tolerable dose is unknown.

Any specific human protocol you find — a milligram figure, a cycle length, a timing relative to training — was written by someone who did not have this information either. That is not a claim that such protocols are dangerous. It is a statement of what they are: guesses presented with the confidence of instructions.

## The interactions nobody can tell you about

For most compounds, the interaction section is a list. For this one, the honest content is an explanation of why the list cannot be written.

Drug interactions are worked out empirically. You find out which liver enzymes metabolise a compound, then you test it against drugs that use the same enzymes and see whose clearance changes. That work has not been published for SLU-PP-332. So the specific question — does this affect how you process your statin, your thyroid medication, your antidepressant — has no answer, and anyone who gives you one is inventing it.

What can be reasoned about is the mechanism, and two things follow from it.

Anything else that drives mitochondrial biogenesis or fat oxidation is pushing in the same direction. That includes AMPK activators like metformin and the research compounds in that class, PPAR agonists, thyroid hormone and its analogues, and to a lesser extent the fibrates. Stacking two systemic metabolic reprogrammers without any human data on either is compounding an unknown with an unknown.

Anything that stresses the heart deserves particular caution, because the Circulation study established that this mechanism acts on cardiac muscle. That is not a warning that it damages the heart — in a failing heart it helped. It is a statement that the heart is in scope, so stimulants, thyroid excess, and anything that raises cardiac workload are being added to a compound that is already changing how cardiac muscle handles fuel.

The mitochondria-dense organs are the ones to watch in principle: heart, kidney, liver, skeletal muscle, brain. Two of the four published studies are about the heart and the kidney specifically, which tells you the mechanism reaches both.

## What is not known, stated plainly

There are no human studies. Not a phase I, not a safety study, not a single-dose pharmacokinetic run in volunteers. Every number attached to this compound came out of a mouse or a cell culture dish.

There is no human dose. The doses quoted in the research are milligrams per kilogram given to mice, usually by injection. Scaling an animal dose to a human is not arithmetic — it depends on how fast each species clears the compound, and no human clearance data exists. Any specific human protocol you encounter for this compound was invented by whoever wrote it.

There is no long-term data in any species. The mouse studies ran for weeks. Nothing is published about a year of exposure in any animal.

The obvious theoretical concern has not been tested. Building mitochondria and driving fat oxidation across every tissue that carries ERR — heart, kidney, liver, muscle, brain — is a large systemic intervention. Exercise produces the same adaptations but produces them gradually, locally, in proportion to the work done, and with every other adaptation of training arriving alongside. A drug does not have that self-limiting quality. What happens when you drive the programme continuously and without the training is an open question, not a resolved one.

It is not a peptide. It is a small molecule, and the "SLU" in the name is Saint Louis University, where the chemistry was done. It is sold beside peptides and constantly called one.

## How to read the numbers that circulate

Four figures come up constantly: 70 percent longer running time, 45 percent further distance, roughly ten times less fat gained, 12 percent of body weight lost. All four trace back to the two studies above and to the university press coverage of them. None is fabricated. Each is worth reading with two things in mind.

The first is what the comparison was. "70 percent longer" is against untreated mice in the same experiment, not against trained mice. The question the study answered is "does this compound raise exercise capacity in an animal that has not trained," and the answer was yes. The question it did not ask is "does this compound raise exercise capacity more than training would," which is the question a person considering it is actually asking.

The second is the species gap, which for metabolic endpoints specifically is wider than most people assume. A mouse has a resting metabolic rate roughly seven times an adult human's per unit of mass. It carries a proportionally large amount of brown fat, the heat-generating tissue that adult humans have very little of, and brown fat is where a lot of drug-induced energy expenditure in mice actually happens. Mice housed at ordinary laboratory temperature are mildly cold-stressed, which means they are already burning energy to stay warm, and interventions that raise energy expenditure look better under that condition than they do at thermoneutrality. This is not a niche objection. It is the single most common reason obesity compounds that transform mice do nothing in people, and the history of the field is largely a list of them.

So the figures are real measurements of a real effect in an animal whose energy metabolism does not work like yours. That is the correct amount of weight to give them: enough to make the mechanism worth pursuing, not enough to predict what happens in a person.

## What it is actually useful for thinking about

The honest reason to pay attention to SLU-PP-332 is not that it is a shortcut. It is that it demonstrated something specific and previously unproven: that a single small molecule can switch on a meaningful part of the endurance-training programme in a living animal, including the fibre-type shift, and that doing so improves metabolic disease in that animal. Before this compound, ERRα was considered close to undruggable. That is a real scientific result and it will produce better molecules than this one.

What it does not demonstrate is that any of this works in a person, at any dose, with any safety margin. There is no evidence either way, because the experiment has not been done.

Anyone treating a mouse chemical tool as an exercise substitute should be clear about what they are actually doing: taking a compound with no human data, no established dose, no safety profile, and a mechanism that acts on every mitochondria-rich organ including the heart. That is not a caution bolted onto the end of an article. It is the accurate description of the compound's position in 2026, and it is the same thing the researchers who made it have said in print.

Everything above is what the published record supports. None of it is medical advice, and SLU-PP-332 is sold for research use only, not for human consumption.


## Sources

1. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity — https://pubmed.ncbi.nlm.nih.gov/36988910/
2. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity — https://pubmed.ncbi.nlm.nih.gov/36988910/
3. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity — https://pubmed.ncbi.nlm.nih.gov/36988910/
4. A Synthetic ERR Agonist Alleviates Metabolic Syndrome — https://pubmed.ncbi.nlm.nih.gov/37739806/
5. A Synthetic ERR Agonist Alleviates Metabolic Syndrome — https://pubmed.ncbi.nlm.nih.gov/37739806/
6. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function — https://pubmed.ncbi.nlm.nih.gov/37961903/
7. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney — https://pubmed.ncbi.nlm.nih.gov/37717940/